FGFR4 kinase mutants are inhibited by PD170734

Stable Identifier
R-HSA-2046363
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Treatment of cells expressing FGFR4 N535K or V550E with the in vitro FGFR inhibitor PD170734 reduces the levels of receptor autophosphorylation and increases the activation of caspase-3 and the number of cells undergoing apoptosis (Taylor, 2009).

Literature References
PubMed ID Title Journal Year
19809159 Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models

Taylor JG, 6th, Cheuk, AT, Tsang, PS, Chung, JY, Song, YK, Desai, K, Yu, Y, Chen, QR, Shah, K, Youngblood, V, Fang, J, Kim, S, Yeung, C, Helman, LJ, Mendoza, A, Ngo, V, Staudt, LM, Wei, JS, Khanna, C, Catchpoole, D, Qualman, SJ, Hewitt, SM, Merlino, G, Chanock, SJ, Khan, J

J Clin Invest 2009
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
rhabdomyosarcoma 3247 Rhabdomyosarcoma NOS (morphologic abnormality), rhabdomyosarcoma, Rhabdomyosarcoma, no subtype (morphologic abnormality), rhabdomyoblastoma, Rhabdomyosarcoma (disorder)
Authored
Reviewed
Created
Cite Us!